<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086878</url>
  </required_header>
  <id_info>
    <org_study_id>BHP031</org_study_id>
    <secondary_id>2P30AI060354-06</secondary_id>
    <secondary_id>3R24TW007988-01S1</secondary_id>
    <nct_id>NCT01086878</nct_id>
  </id_info>
  <brief_title>Safety of Cotrimoxazole in HIV- and HAART-exposed Infants</brief_title>
  <official_title>Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Initiative for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The American Society of Tropical Medicine and Hygiene</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health (HSPH)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if prophylactic cotrimoxazole makes severe anemia&#xD;
      or neutropenia more common in infants exposed to maternal HIV and combination antiretroviral&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year, more than 2 million children are born to HIV-infected women. The World Health&#xD;
      Organization (WHO) recommends that these infants receive cotrimoxazole (CTX) prophylaxis&#xD;
      starting at 4-6 weeks of age until the period of infant HIV transmission risk is over, and&#xD;
      the infant is known to be HIV-uninfected. There is also increasing interest in studying CTX&#xD;
      prophylaxis given to all infants of HIV-infected women at the time of initiation of&#xD;
      replacement feeding, regardless of infant HIV infection status, to mitigate the high risk of&#xD;
      infant morbidity and mortality associated with formula feeding in the developing world.&#xD;
      However, infant in utero exposure to maternal antiretroviral drugs can lead to hematologic&#xD;
      toxicities in infants. It is critical to know whether infant CTX prophylaxis exacerbates the&#xD;
      hematologic toxicity associated with perinatal ARV exposure. This question, with broad public&#xD;
      health implications, has never been studied.&#xD;
&#xD;
      We will study the hematologic toxicity associated with CTX prophylaxis given to infants&#xD;
      exposed to maternal HAART in Botswana. We will use existing data from a large cohort that did&#xD;
      not receive CTX, and enroll a smaller cohort that does receive CTX according to Botswana&#xD;
      national guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of severe or life-threatening anemia</measure>
    <time_frame>between 1 to 6 months of life</time_frame>
    <description>incidence of severe or life-threatening anemia (as defined by DAIDS toxicity tables, 2004) between 1 and 6 month of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of severe or life-threatening neutropenia</measure>
    <time_frame>between 1 to 6 months of life</time_frame>
    <description>incidence of severe or life-threatening neutropenia (as defined by DAIDS toxicity tables, 2004) between 1 and 6 month of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite severe morbidity and mortality</measure>
    <time_frame>between 1 and 6 months of life</time_frame>
    <description>Composite of severe morbidity (grade 3 or 4 illnesses, DAIDS toxicity tables, 2004), hospitalization, and mortality.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Infant, Newborn</condition>
  <condition>Anemia</condition>
  <condition>Neutropenia</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Cotrimoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cotrimoxazole</intervention_name>
    <description>Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:&#xD;
less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim&#xD;
greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim</description>
    <arm_group_label>Cotrimoxazole</arm_group_label>
    <other_name>Bactrim</other_name>
    <other_name>Septrim</other_name>
    <other_name>Cotrim</other_name>
    <other_name>Septra</other_name>
    <other_name>trimethoprim/sulfamethoxazole</other_name>
    <other_name>trimethoprim-sulfamethoxazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Both maternal and infant criteria need to be met:&#xD;
&#xD;
        Maternal Inclusion Criteria:&#xD;
&#xD;
          -  documented HIV infection&#xD;
&#xD;
          -  taking 3-drug highly active antiretroviral therapy at any point during pregnancy&#xD;
             (note: can include 2 NRTI+NNRTI, 2NRTI+PI, or 3 NRTI)&#xD;
&#xD;
          -  21 years of age or older, and able and willing to sign informed consent&#xD;
&#xD;
          -  Proof of Botswana Citizenship&#xD;
&#xD;
        Maternal Exclusion Criteria:&#xD;
&#xD;
          -  involuntary incarceration&#xD;
&#xD;
        Infant Inclusion Criteria:&#xD;
&#xD;
          -  younger than 42 days of age&#xD;
&#xD;
          -  able to be brought to regular visits at study clinic until at least 6 months&#xD;
             postpartum&#xD;
&#xD;
        Infant Exclusion Criteria:&#xD;
&#xD;
          -  known pre-existing birth anomalies resulting in a high probability that the baby will&#xD;
             not survive to 6 months&#xD;
&#xD;
          -  known hypersensitivity to cotrimoxazole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin Lockman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health (HSPH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottish Livingstone Hospital</name>
      <address>
        <city>Molepolole</city>
        <state>Kweneng</state>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Marina Hospital</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Shahin Lockman, MD</name_title>
    <organization>Harvard School of Public Health</organization>
  </responsible_party>
  <keyword>Antiretroviral Therapy, Highly Active</keyword>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>anemia</keyword>
  <keyword>neutropenia</keyword>
  <keyword>safety</keyword>
  <keyword>hematologic toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

